HeparDx
Diagnosis and staging of MASH (Metabolic dysfunction-associated steatohepatitis) and Liver Fibrosis
Clinical ValidationActive
Key Facts
Indication
Diagnosis and staging of MASH (Metabolic dysfunction-associated steatohepatitis) and Liver Fibrosis
Phase
Clinical Validation
Status
Active
Company
About MetaDeq Diagnostics
MetaDeq Diagnostics is an early-stage diagnostics company targeting the massive and growing market for MASH (formerly NASH) and liver fibrosis detection. Its core innovation, HeparDx, is a blood-based test validated in a 250-patient prospective study, demonstrating >95% accuracy in diagnosing MASH against the biopsy gold standard. The company is positioned to capitalize on new ADA screening guidelines and the recent FDA approval of the first MASH drug, Rezdiffra, which creates a pressing need for non-invasive diagnostics for patient identification and treatment monitoring.
View full company profile